| Affymax and Takeda Report Additional Analyses of Peginesatide Phase 3 Studies ... - istockAnalyst.com (press release) |
|
|
istockAnalyst.com (press release) Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., US, today announced results from additional analyses of the EMERALD Phase 3 studies that evaluated the investigational agent peginesatide in dialysis patients with ... Affymax and Takeda Report Additional Analyses of Peginesatide Phase 3 Studies ... MarketWatch (press release) Affymax and Takeda Report Additional Analyses of Peginesatide Phase 3 Studies |